Document -

Attana Application Note: Early detection of clinical failure

The objective of this application note was to evaluate newly developed therapeutic antibodies in a biologically relevant context (cells) in order to detect failing candidates at an earlier stage. Among other things, it was found that real-time screening of drug candidates in a synthetic and in a cellular context together provides highly informative and biologically relevant data.
go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.pdf
Download

Topics

  • Medical research

Categories

  • biosensor
  • attana cell 200
  • cells

Related content

  • Biosensor- Attana Cell 200, label free, real time kinetics on cells

    Revolutionary Swedish invention can potentially improve drug development! Attana AB introduces the Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body.

  • Biotech companies - Ways to work more efficiently

    Ernst & Young recently released their 24th annual report Beyond borders: global biotechnology report 2010, presenting, among other things, five guiding principles for biotech companies working in the new economy where funding is scarce and customers careful: